To Develop Gut-Safe Pain Drug
AstraZeneca, Pozen Entering PN Deal Worth Up To $375M
Once-hurting Pozen Inc. got whopping relief from AstraZeneca plc in the form of a potential $375 million deal, with $40 million up front, to develop fixed-dose combinations of naproxen and AstraZeneca's esomeprazole for chronic pain. (BioWorld Today)
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.